Genentech, a member of the Roche Group, marked the structural completion of its $2 billion biomanufacturing facility in Holly Springs, North Carolina, during a topping-out ceremony on Monday.
The milestone represents continued on-time progress for the project, which broke ground in August 2025 following an initial investment announcement in May 2025. Genentech expanded the facility's scope in January 2026, reinforcing confidence in the region's workforce and long-term potential. Once operational, the plant will produce next-generation treatments for metabolic conditions, including obesity, and incorporate advanced biomanufacturing, automation, robotics and digital manufacturing technologies.
The facility will feature an AI-powered digital twin—a virtual model of operations designed to simulate scenarios and optimize reliability—aimed at improving production efficiency, reducing waste and accelerating the delivery of critical medicines. Genentech estimates the plant will support more than 2,000 jobs, including over 500 high-wage manufacturing roles and more than 1,500 construction jobs.
The investment aligns with Roche and Genentech's broader $50 billion commitment to research, development and manufacturing infrastructure in the U.S. The company's current U.S. footprint includes 13 manufacturing sites, 15 R&D locations and approximately 25,000 employees across 24 sites in eight states.
Genentech has operated for 50 years, advancing scientific innovation and fostering the biotechnology industry. The Holly Springs facility extends this legacy by strengthening capabilities to translate future breakthroughs into medicines over the next five decades.
Teresa Graham, CEO of Roche Pharmaceuticals, said the investment reflects long-term confidence in U.S. biomedical innovation. Fritz Bittenbender, Genentech's SVP of Public Affairs and Access, emphasized the facility's role in strengthening the U.S.-based supply chain and empowering a skilled workforce. North Carolina officials highlighted the project's contribution to the state's life sciences ecosystem and job creation.
Genentech was founded 50 years ago and remains headquartered in South San Francisco, California.
